OBJECTIVES: Wet Age-Related Macular Degeneration (wAMD) is a degenerative disorder of the macula associated with the aging process and one of the main causes of severe and irreversible loss of vision in people older than 40 years. Intravitreal-aflibercept is an antiangiogenic therapy that leads to results as good as ranibizumab’s, with less injections and monitoring. This study sought to estimate the economic consequences of intravitreal-aflibercept vs. ranibizumab on-label, once it was proved that there is no statistically-significant differences (5% equivalence margin) in efficacy and safety profiles, in the management of patients with wAMD, from the Mexican Institutional Payer Perspective. METHODS: a cost-minimization set was developed for the comparison between intravitreal-aflibercept (2mg each 8 weeks after a 3-monthly loading dose injections to complete a first year, followed by pro re nata (PRN) applications to complete a second year), vs. ranibizumab on-label (0.5mg each 4 weeks during a first year, followed by PRN applications for a second year) comparison, after proving no statistically-significant differences (5% equivalence margin) in efficacy and safety profiles , based in the results reported in a head-to-head, multicentric, dobule-blind phase III clinical trial (VIEW trial). Costs were discounted at 5%/year through a 2-year time horizon. The costs are expressed in 2014 US$ and correspond to Mexican public healthcare institutions. Univariate sensitivity analyses were performed. RESULTS: Total expected costs for each alternative in the cost-minimization set were: intravitreal-aflibercept US$9,805 (US$6,946 related to drug and US$2,859 to monitoring/application) and ranibizumab on-label US$14,323 (US$8,989 trelated to drug and US$5,334 to monitoring/application). CONCLUSIONS: The results indicate that intravitreal-aflibercept is a cost-saving option over ranibizumab on-label for the treatment of wAMD patients in Mexico, from the perspective of the Institutional Payer, without compromising the results in health.